【DaYan BioMedical*】The Company's Board of Directors Approved the Consolidated Financial Statements for Q1 2026

1. Date of report to or resolution by the board of directors: 2026/05/07 2. Date of approval by the audit committee: 2026/05/07 3. Reporting period of financial report or self-compiled financial information for the year from (YYYY/MM/DD) to (YYYY/MM/DD): 2026/01/01~2026/12/31 4. Cumulative operating revenue from January 1 to the end of this period (in thousands of NTD): 463,842 5. Cumulative operating gross profit (gross loss) from January 1 to the end of this period (in thousands of NTD): 278,740 6. Cumulative operating income (loss) from January 1 to the end of this period (in thousands of NTD): 62,176 7. Cumulative net profit (net loss) before tax from January 1 to the end of this period (in thousands of NTD): 140,409 8. Cumulative net profit (net loss) for the current period from January 1 to the end of this period (in thousands of NTD): 104,355 9. Cumulative net profit (loss) attributable to owners of parent from January 1 to the end of this period (in thousands of NTD): 104,355 10. Cumulative basic earnings per share (loss) from January 1 to the end of this period (in NTD): 0.13 11. Total assets at the end of the period (in thousands of NTD): 6,115,807 12. Total liabilities at the end of the period (in thousands of NTD): 597,910 13. Equity attributable to owners of parent at the end of the period (in thousands of NTD): 5,517,897 14. Other matters that need to be specified: None